BRPI0620229A8 - formulação - Google Patents

formulação

Info

Publication number
BRPI0620229A8
BRPI0620229A8 BRPI0620229A BRPI0620229A BRPI0620229A8 BR PI0620229 A8 BRPI0620229 A8 BR PI0620229A8 BR PI0620229 A BRPI0620229 A BR PI0620229A BR PI0620229 A BRPI0620229 A BR PI0620229A BR PI0620229 A8 BRPI0620229 A8 BR PI0620229A8
Authority
BR
Brazil
Prior art keywords
formulation
arabinofuranosylcytosine
palmitoyl
deoxy
cyano
Prior art date
Application number
BRPI0620229A
Other languages
English (en)
Inventor
Selkirk Alistair
Westwood Robert
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Publication of BRPI0620229A2 publication Critical patent/BRPI0620229A2/pt
Publication of BRPI0620229A8 publication Critical patent/BRPI0620229A8/pt
Publication of BRPI0620229B1 publication Critical patent/BRPI0620229B1/pt
Publication of BRPI0620229B8 publication Critical patent/BRPI0620229B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

formulação. a presente invenção refere-se a uma formulação farmacêutica que compreende (1) uma cápsula, e (ii) um núcleo compreendendo 2'-ciano- 2-deóxi-n4-palmitoil-1 -13-d-arabinofuranosilcitosina cristalina e um veículo líquido.
BRPI0620229A 2005-12-23 2006-12-22 formulações farmaceuticas e processos de produção da ditas formulações BRPI0620229B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0526419.7A GB0526419D0 (en) 2005-12-23 2005-12-23 Formulation
GB0526419.7 2005-12-23
PCT/GB2006/004927 WO2007072061A2 (en) 2005-12-23 2006-12-22 Crystalline pyrimidine nucleoside derivatives suspensions in capsules

Publications (4)

Publication Number Publication Date
BRPI0620229A2 BRPI0620229A2 (pt) 2011-11-01
BRPI0620229A8 true BRPI0620229A8 (pt) 2018-01-02
BRPI0620229B1 BRPI0620229B1 (pt) 2020-09-15
BRPI0620229B8 BRPI0620229B8 (pt) 2021-05-25

Family

ID=35841215

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0620229A BRPI0620229B8 (pt) 2005-12-23 2006-12-22 formulações farmaceuticas e processos de produção da ditas formulações

Country Status (16)

Country Link
US (1) US8497291B2 (pt)
EP (1) EP1962814B1 (pt)
JP (2) JP5443763B2 (pt)
CN (1) CN101346132B (pt)
AU (1) AU2006327951B2 (pt)
BR (1) BRPI0620229B8 (pt)
CA (1) CA2633308C (pt)
DK (1) DK1962814T3 (pt)
ES (1) ES2672106T3 (pt)
GB (1) GB0526419D0 (pt)
HU (1) HUE039368T2 (pt)
IL (1) IL192348A (pt)
PT (1) PT1962814T (pt)
RU (1) RU2428972C2 (pt)
TR (1) TR201808182T4 (pt)
WO (1) WO2007072061A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088167A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
GB0625283D0 (en) 2006-12-19 2007-01-24 Cyclacel Ltd Combination
WO2008132443A1 (en) * 2007-04-25 2008-11-06 Cyclacel Limited Use of sapacitabine to treat proliferative disease
US8124593B2 (en) 2007-11-05 2012-02-28 Cyclacel Limited Methods of treatment using sapacitabine
GB0808357D0 (en) 2008-05-08 2008-06-18 Cyclacel Ltd Process
KR101667641B1 (ko) 2008-06-09 2016-10-20 싸이클라셀 리미티드 데시타빈 및 프로카인과 같은 ｄｎａ 메틸전이효소 저해제와 사팍시타빈 또는 ｃｎｄａｃ의 조합
FI2431376T4 (fi) * 2009-05-15 2024-03-13 Delta Fly Pharma Inc 1-(2'-syano-2'-deoksi-beeta-D-arabinofuranosyyli)sytosiinimonohydrokloridin uusi vakaa kide
CN103037851A (zh) 2010-06-02 2013-04-10 安斯泰来德国有限公司 苯达莫司汀的口服剂型
HUE046177T2 (hu) 2011-04-14 2020-02-28 Cyclacel Ltd Szapacitabin és decitabin kombinációjának adagolási rendje akut mieloid leukémia kezelésére
JP5873375B2 (ja) * 2012-04-03 2016-03-01 中日本カプセル 株式会社 ソフトカプセル及びソフトカプセルの製造方法
WO2013171473A1 (en) 2012-05-15 2013-11-21 Cyclacel Limited Dosage regimen for sapacitabine and seliciclib
AU2014222389B2 (en) 2013-02-28 2018-11-29 Pronova Biopharma Norge As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
CN106963742B (zh) * 2016-11-07 2021-02-23 澳门大学 中药固液胶囊及其制备方法
WO2019081951A1 (en) 2017-10-27 2019-05-02 Cyclacel Limited DOSAGE REGIME
WO2021079129A1 (en) 2019-10-24 2021-04-29 Cyclacel Limited Dosing regimen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2559917B2 (ja) * 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
WO1992018504A1 (en) * 1991-04-22 1992-10-29 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND ANTI-INFLAMMATORY CONTAINING THE SAME
RU2085557C1 (ru) * 1991-09-30 1997-07-27 Санкио Компани Лимитед Производные нуклеозидов пиримидина или их фармацевтически приемлемые соли и способ их получения
DE4322826A1 (de) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
US5599922A (en) * 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
KR19980073479A (ko) * 1997-03-14 1998-11-05 한스루돌프하우스, 니콜케르커 사이클로스포린-함유 연질캅셀제
NL1003503C2 (nl) * 1996-07-04 1998-01-07 Negma Steba International Dev Farmaceutische samenstelling voor orale toediening.
GB9918885D0 (en) * 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules
JP3748536B2 (ja) * 2001-02-09 2006-02-22 三共株式会社 ピリミジンヌクレオシド誘導体の結晶
US6908906B2 (en) * 2001-02-09 2005-06-21 Sankyo Company, Limited Crystalline forms of pyrimidine nucleoside derivative
ATE374602T1 (de) * 2001-12-21 2007-10-15 Supernus Pharmaceuticals Inc Orale kapselformulierung mit verbesserter physikalischer stabilität
JP5096658B2 (ja) * 2003-10-06 2012-12-12 株式会社三協 生物学的利用能を向上させたソフトカプセル
US20050249802A1 (en) * 2004-05-06 2005-11-10 The Procter & Gamble Company Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients
GB0413730D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use

Also Published As

Publication number Publication date
BRPI0620229A2 (pt) 2011-11-01
HK1126412A1 (en) 2009-09-04
CN101346132A (zh) 2009-01-14
JP5443763B2 (ja) 2014-03-19
GB0526419D0 (en) 2006-02-08
PT1962814T (pt) 2018-06-22
US8497291B2 (en) 2013-07-30
IL192348A (en) 2016-02-29
AU2006327951A1 (en) 2007-06-28
CA2633308C (en) 2014-06-17
WO2007072061A2 (en) 2007-06-28
DK1962814T3 (en) 2018-08-06
IL192348A0 (en) 2009-08-03
RU2008130411A (ru) 2010-01-27
AU2006327951B2 (en) 2012-09-06
BRPI0620229B8 (pt) 2021-05-25
TR201808182T4 (tr) 2018-07-23
HUE039368T2 (hu) 2018-12-28
ES2672106T3 (es) 2018-06-12
CA2633308A1 (en) 2007-06-28
JP2009520797A (ja) 2009-05-28
BRPI0620229B1 (pt) 2020-09-15
EP1962814B1 (en) 2018-04-25
JP2013189463A (ja) 2013-09-26
RU2428972C2 (ru) 2011-09-20
WO2007072061A3 (en) 2007-10-25
US20090074856A1 (en) 2009-03-19
CN101346132B (zh) 2013-01-16
EP1962814A2 (en) 2008-09-03

Similar Documents

Publication Publication Date Title
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
UY29856A1 (es) Forma cristalina 8d del clorhidrato de la ivabradina, su procedimiento de preparación, y las composiciones farmaceuticas que la contienen
BRPI0809667A2 (pt) Composto, medicamento e composição farmacêutica que o contém e uso do composto
SV2008003088A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
AR052925A1 (es) Forma cristalina betad del clorhidrato de ivabradina, un procedimiento para su preparacion y composiciones farmaceuticas que la contienen
GT200800276A (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
ECSP099776A (es) Moduladores de la gamma secretasa
CO6362017A2 (es) Peptidos antivirales terapeuticos
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
EP2153831A4 (en) ANTIERMÜDUNGSMITTEL AND ORAL COMPOSITION, BOTH WITH ANDROGRAPHOLIDE AS ACTIVE INGREDIENTS
DE502007005902D1 (de) -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
GT200600200A (es) Composicion farmaceutica que contienen gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato
CL2007003593A1 (es) Composicion farmaceutica que comprende fluoresceina pura; procedimiento de preparacion de la fluoresceina.
CR9391A (es) Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
EA200900780A1 (ru) Аналоги эпотилона, модифицированные в положениях c12-c13, как противораковые лекарственные средства
BRPI0620229B8 (pt) formulações farmaceuticas e processos de produção da ditas formulações
BRPI0408848B8 (pt) composições farmacêuticas de complexo de ciclodextrina-cladribina complexo, usos do referido complexo, bem como processos para a sua preparação
UA106200C2 (uk) Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину
BRPI0506779A (pt) formulação de sorvete, e, sorvete
EP2053038A4 (en) AMINO ALCOHOL DERIVATIVE AND THESE IMMUNOSUP PRESSIVES CONTAINING ACTIVE INGREDIENTS
DE602006017724D1 (de) Salicylsäurederivate
UY29236A1 (es) 2-alcoxi-3,4,5-trihidroxi-alquilamidas. su preparación, composiciones que las contienen y su utilización.
NO20064808L (no) Orale matrixformuleringer med licarbazepin
IL190063A (en) The history of cycloalkanes is preserved, their medicinal preparations and their uses

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: ESCLARECA O DEPOSITANTE A DIVERGENCIA EXISTENTE NO NOME DO INVENTOR ROBERT WESTWOOD CONSTANTE DA PUBLICACAO WO NO 2007/072061 DE 28/06/2007 E O EXISTENTE NA PETICAO INICIAL.

B25G Requested change of headquarter approved

Owner name: CYCLACEL LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: CYCLACEL LIMITED (GB)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/12/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2754 DE 17-10-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.